Leading Companies

TherAchon AG

Therachon is a global biotechnology company (headquartered in Basel) committed to making a difference in the lives of patients living with serious rare conditions. Therachon is assembling a growing best-in-disease pipeline that shows great promise in both Achondroplasia (short-limbed dwarfism, which affects 250'000 worldwide) and Short Bowel Syndrome. TA-46 for the therapy of achondroplasia developed by Therachon has completed clinical phase 1 and received Orphan Drug Designation from the European Medicines Agency and the U.S. Food and Drug Administration. As a result of Therachon's outstanding work, Therachon was acquired by Pfizer in 2019 for USD 340 million (milestones not inclued). Bevor being acquired by Pfizer, Therachon spun-off its apraglutide development program into a separate, independent company called VectivBio also headquartered in Basel. This program for short bowel syndrome is currently in Phase 2 development.

TherAchon AG

Grosspeteranlage 29
4052 Basel
Switzerland


Secteurs
Bio Technology (Biotech)
Life Science
Country of Origin
France
En savoir plus sur le sujet
Partager

Partenaire Premium

Partenaires stratégiques

Partenaire institutionnel

Programme officiel